NYSE:PFE - Pfizer Stock Price, Price Target & More

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Thursday, June 28th. Shareholders of record on Friday, August 3rd will be paid a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 annualized dividend and a yield of 3.64%. The ex-dividend date of this dividend is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer announced that its Board of Directors has approved a share repurchase plan on Tuesday, December 19th 2017, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its shares are undervalued.

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.03. The biopharmaceutical company had revenue of $12.91 billion for the quarter, compared to analysts' expectations of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The company's revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.69 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $54.45 billion.

20 Wall Street analysts have issued 1 year price objectives for Pfizer's stock. Their predictions range from $36.00 to $45.00. On average, they anticipate Pfizer's stock price to reach $40.4167 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Ratings for Pfizer.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Pfizer saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 59,174,572 shares, a decline of 8.5% from the June 15th total of 64,685,349 shares. Based on an average daily volume of 21,034,138 shares, the days-to-cover ratio is presently 2.8 days. Currently, 1.0% of the shares of the company are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News articles about PFE stock have trended somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pfizer earned a media sentiment score of -0.06 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.74 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.66%), Bank of Montreal Can (0.37%), Hexavest Inc. (0.10%), NN Investment Partners Holdings N.V. (0.09%), Swedbank (0.06%) and Retirement Systems of Alabama (0.05%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Bank of Montreal Can, Hartford Investment Management Co., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Assenagon Asset Management S.A., Retirement Systems of Alabama, Swedbank and KAMES CAPITAL plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including Jensen Investment Management Inc., Fisher Asset Management LLC, State of Alaska Department of Revenue, Calamos Advisors LLC, IFM Investors Pty Ltd, Nisa Investment Advisors LLC, Pendal Group Ltd and DnB Asset Management AS. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $37.36.

Pfizer has a market capitalization of $224.13 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.